



Biocon Limited

20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

April 29, 2022

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- BIOCON
---	---

Dear Sir/Madam,

Subject: Presentation and Video Recording of Q4 FY22 Earnings Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), please find enclosed the presentation on Q4 and full year FY22 Earnings Call conducted today i.e. on 29th April, 2022. The same is also available on the website of the Company www.biocon.com.

Further, the Video Recording w.r.t. the Earnings Call is also available on the website of the Company at <https://www.biocon.com/news-biocon/video-gallery-biocon/quarterly-statements-biocon/>.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank



Mayank Verma
Company Secretary & Compliance Officer

Encl. as above



Q4 and full year FY22 Earnings Call

April 29, 2022

A vertical blue-tinted photograph of a laboratory setting. A hand is using a pipette to transfer liquid into a test tube. The background shows a blurred laboratory bench with various pieces of equipment.

Unwavering
Purpose

Safe Harbor Statement

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Q4 and full year FY22 Earnings Call



Unwavering
Purpose

Opening Remarks



➤ Biocon reported revenues of \$1.1 billion (₹8,397 Crores)

➤ Transformative acquisition of Viatris' biosimilars business for \$3.335 billion

➤ Biocon awarded by EcoVadis in the 'Bronze' category for its sustainability practices



'Pipeline is our lifeline'



1 Subject to completion of the acquisition of Covishield Technologies Private Limited (CTPL) | 2 Expected to be included in BBL portfolio post the completion of BBL's acquisition of Viatrix's biosimilar business (Viatrix has global rights to the program partnered with Momenta) | 3 Based on 2021 originator and biosimilar reported sales

Board Update



Unwavering
Purpose

Board Update

Naina Lal Kidwai joins Biocon Limited Board as Additional Director

- A veteran banker and business leader
- Past President of FICCI
- An MBA from Harvard Business School
- Recipient of several awards including the Padma Shri for her contribution to trade & industry.
- Serves as an Additional Director and Senior Advisor for Rothschild India, and Senior Advisor Advent International, Non-Executive Director on boards of Holcim, Max Financial Services etc.
- Retired in 2015 as Chairman of HSBC India & Executive Director of HSBC Asia Pacific



Financial Highlights Q4 and full year FY22



Unwavering
Purpose

Financial Highlights: Q4FY22

		Q 4 F Y 2 2	Q 4 F Y 2 1	
Revenue	+21%	₹2,476Cr	₹2,048Cr	Biosimilars +48% Generics +26% Research Services +15% Dilution Gain in Bicara of ₹30Cr vs ₹160Cr in Q4FY21
Core EBITDA*	+37%	₹815Cr	₹594Cr	Mark-to-market loss on investments of ₹6Cr Forex Gain of ₹2Cr vs ₹7Cr in Q4FY21
<i>% margin</i>		33%	32%	
EBITDA	+3%	₹659Cr	₹641Cr	Gross R&D spend at ₹232Cr R&D spend in P&L ₹191Cr
<i>% margin</i>		27%	31%	
Profit Before Tax before Exceptional Items	+9%	₹384Cr	₹353Cr	Exceptional Loss of ₹41Cr vs Gain of ₹13Cr in Q4FY21
<i>% margin</i>		15%	17%	
Net Profit (Before exceptional items)		₹262Cr	₹253Cr	Net Profit after exceptional items at ₹239Cr
<i>% margin</i>		11%	13%	

*Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, mark-to-market loss on investments and licensing income

Financial Highlights: FY22

		FY 22	FY 21	
Revenue	+14%	₹8,397Cr	₹7,398Cr	Biosimilars +24% Research Services +19% Generics -1% Dilution Gain in Bicara of ₹30Cr vs ₹160Cr in FY21
Core EBITDA*	+18%	₹2,669Cr	₹2,270Cr	Mark-to-market loss on investments of ₹28Cr; Forex Gain of ₹58Cr vs loss of ₹9Cr in FY21
<i>% margin</i>		32%	31%	
EBITDA	+14%	₹2,183Cr	₹1,907Cr	Gross R&D spend at ₹711Cr R&D spend in P&L ₹595Cr
<i>% margin</i>		26%	26%	
Profit Before Tax before Exceptional Items	+4%	₹1,094Cr	₹1,055Cr	Exceptional Loss at ₹111Cr
<i>% margin</i>		13%	14%	
Net Profit (Excluding Exceptional loss)		₹722Cr	₹744Cr	Net Profit after exceptional items at ₹648Cr
<i>% margin</i>		9%	10%	

*Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, mark-to-market loss on investments and licensing income

Generics Q4 and full year FY22



Unwavering
Purpose

Generics: Q4FY22 and full year FY22

KEY Q4 HIGHLIGHTS

- Robust sequential and YoY growth in Q4 driven by API sales ramp up, new launches in the US & normalization of operations
- Posaconazole and Dorzolamide, launched in the US; 1st MoW market launch in Mexico; 1st approval in Singapore & in the UAE
- Successful site inspection by Health Canada at Bengaluru API manufacturing unit
- On track to qualify & validate Vizag API facility in FY23; to commence new manufacturing expansion projects in Hyderabad & Bengaluru
- Diversified renewable power consumption to solar & wind energy

Q4FY22

Q4FY21

Revenue

₹717Cr

₹570Cr

+26%

Profit Before Tax (PBT)

₹116Cr

₹73Cr

+59%

16% of revenue

13% of revenue

FY22

FY21

Revenue

₹2,341Cr

₹2,363Cr

Profit Before Tax (PBT)

₹261Cr

₹291Cr

11% of revenue

12% of revenue

Biosimilars

Q4 and full year FY22



Unwavering
Purpose

Biosimilars: Q4 and full year FY22 Financials

	Q4 FY22	Q4 FY21		FY22	FY21	
Revenue	₹982Cr	₹664Cr	+48%	₹3,464Cr	₹2,800Cr	+24%
Core EBITDA*	₹382Cr	₹215Cr	+78%	₹1,320Cr	₹1,010Cr	+30%
<i>% margin</i>	39%	33%		39%	36%	
Profit Before Tax before Exceptional Items	₹144Cr	₹69Cr	+109%	₹543Cr	₹365Cr	+49%
<i>% margin</i>	15%	10%		16%	13%	

*Core EBITDA defined as EBITDA before R&D, forex, licensing and mark-to-market loss on investments

Biosimilars: Key Highlights

COMMERCIAL PERFORMANCE

- Interchangeable bGlargine to potentially end CY 2022 with mid to high teens market share
- Oncology franchise continues strong performance bolstered by bBevacizumab launch in EU
- US launches of biosimilar Aspart, Bevacizumab and Adalimumab key growth drivers of Viatriis-led business
- BBL awarded a three-year contract for Insugen® in Malaysia, valued at \$90m
- In FY22, Branded Formulations India (BFI) business recorded 35% revenue growth YoY

PIPELINE UPDATES

- Unpartnered wave 2 programs, bDenosumab and bUstekinumab, entered clinical development
- BBL Wave 2 biosimilar portfolio to addresses ~\$20b market opportunity*

TRANSACTION UPDATES

- Exercised the option to acquire Viatriis' rights in bAflibercept
- SILS and Viatriis deals on track for closing in H2 CY 2022

*Based on 2021 originator sales

Novels Q4FY22



Unwavering
Purpose

Novels: Q4FY22

KEY HIGHLIGHTS

▶ **Pivotal Phase III clinical study of Itolizumab for aGVHD* initiated in March 2022**

▶ **Bicara# initiated dose expansion cohorts evaluating BCA101 in patients with head and neck, anal canal & cutaneous squamous cell carcinoma**



*Acute Graft-Versus-Host Disease

#In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara Therapeutics Inc. to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.

Research Services
Q4 and full year FY22
Syngene



Unwavering
Purpose

Research Services: Q4FY22 and full year FY22

KEY Q4 HIGHLIGHTS

- Performance across all divisions in Q4
- Particularly strong quarter for Development Services on account of catching up on earlier delayed projects
- Completed Phase III of Hyderabad research facility expansion

Q4FY22

Q4FY21

Revenue

₹758Cr

₹659Cr

+15%

Profit Before Tax (PBT)

₹179Cr

₹158Cr

+14%

24% of revenue

24% of revenue

FY22

FY21

Revenue

₹2,604Cr

₹2,184Cr

+19%

Profit Before Tax (PBT)

₹515Cr

₹434Cr

+19%

20% of revenue

20% of revenue

Concluding Remarks



Unwavering
Purpose

Concluding Remarks

➤ Final Dividend of 10% of face value of each share proposed for FY22

➤ Viatris and Serum deals to drive FY23 Growth



Q&A



Unwavering
Purpose